Research programme: hepatitis C virus therapeutics - Ben-Gurion University/Sorrento Therapeutics
Latest Information Update: 23 Jul 2013
At a glance
- Originator Ben Gurion University
- Developer Ben Gurion University; Sorrento Therapeutics
- Class Antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Hepatitis C
Most Recent Events
- 09 Jul 2013 Early research in Hepatitis C in USA (unspecified route)